Angle PLC - EACR 2025: Innovation in AR Expression Profiling

Rhea-AI Summary

ANGLE plc presented new data at EACR 2025 showcasing their innovative CTC-based assay for Androgen Receptor (AR) expression profiling in prostate cancer. The company developed a novel approach using the Parsortix system and AR immunofluorescence assay, demonstrating high sensitivity in monitoring AR expression levels. Testing on spiked blood samples showed significant AR expression reduction from 80% to 20% with increasing AR-drug concentrations. In clinical validation with 20 mCRPC patients, 50% showed CTC-positive results, all with AR-positive CTCs. The assay addresses a crucial need in the projected $9.8B AR inhibitor market by 2032, offering real-time monitoring capabilities for drug response and resistance in prostate cancer trials. The technology is now available as part of ANGLE's assay menu for pharmaceutical customers.

Positive

• Development of a novel, sensitive assay for monitoring AR expression in prostate cancer patients
• Successful clinical validation in mCRPC patient samples with 50% CTC-positive detection rate
• Addresses significant market opportunity in AR inhibitor market projected at $9.8B by 2032
• Technology now commercially available for pharmaceutical customers in clinical trials

Negative

• None.

ANGLE presents new data at EACR 2025 Highlighting Innovation in Androgen Receptor EXPRESSION profiling

Poster presentation highlights development of a novel CTC-based assay

GUILDFORD, SURREY / ACCESS Newswire / June 17, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the presentation of a poster at the European Association for Cancer Research (EACR) Congress, taking place in Lisbon, Portugal from 16-19 June 2025.

The poster entitled 'Combined microfluidic isolation and immunofluorescence staining of circulating tumour cells for the assessment of Androgen Receptor expression in metastatic prostate cancer blood samples', is being presented during the Biomarkers in Tissue and Blood session on Tuesday 17 June 2025.

This assay addresses a significant unmet need in prostate cancer. The androgen receptor (AR) plays a central role in driving disease growth and progression, and changes in AR can lead to resistance to current treatments and the development of advanced incurable disease known as metastatic castration-resistant prostate cancer (mCRPC). With at least 130 ongoing clinical studies and a projected AR inhibitor market value of US $9.8 billion by 2032, there is growing demand for assays that can monitor AR activity¹.

ANGLE has developed a new approach for repeatable assessment of AR expression in prostate cancer patients using the Parsortix system and ANGLE's AR immunofluorescence assay. The assay was tested on blood spiked with prostate cancer cells exposed to increasing AR drug concentrations. The results showed a clear, statistically significant reduction in AR expression as AR-drug concentration increased, from over 80% AR-positive cells in untreated samples to under 20% at the highest drug level. This demonstrates the assay's high sensitivity and highlights its potential utility for pharmacodynamic assessment, enabling customers to monitor treatment response in real-time.

The assay was then validated in blood samples from 20 patients with mCRPC. 50% of patients were CTC-positive and all CTC-positive patients had AR-positive CTCs enabling the assessment of AR expression levels. CTC clusters, which are known to be up to 100 times more metastatic, were observed in 80% of CTC-positive patients. All CTCs detected were mesenchymal or undergoing EMT, highlighting the importance of using the marker-independent Parsortix system in this patient cohort.

This work demonstrates how ANGLE's Portrait AR workflow enables sensitive, real-time monitoring of AR expression from a simple blood draw. The assay is now available as part of ANGLE's assay menu to support pharma customers with longitudinal biomarker assessment in AR-targeted clinical trials.

The poster will be available on ANGLE's website from 20:00 on Tuesday 17 June: https://angleplc.com/resources/posters/

ANGLE Chief Scientific Officer, Karen Miller, commented:
"This work underscores the value of ANGLE's Parsortix system for enabling detailed protein analysis directly in intact CTCs. The androgen receptor assay development programme has successfully been completed, and we are excited by its potential to repeatably monitor drug response and resistance in prostate cancer trials. Sharing this data at EACR reflects our ongoing commitment to advancing precision oncology with innovative, real-world solutions."

1. https://dataintelo.com/report/androgen-receptor-ar-inhibitor-market

For further information:

ANGLE plc	+44 (0) 1483 343434
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser	+44 (0) 20 3207 7800
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US)	+44 (0) 203 727 1000 +1 (212) 850 5624

For Research Use Only. Not for use in diagnostic procedures.

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix^® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.

Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:

The Parsortix^® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K₂EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on ACCESS Newswire

FAQ

What is the new technology ANGLE presented at EACR 2025?

ANGLE presented a novel CTC-based assay using the Parsortix system and AR immunofluorescence assay for monitoring Androgen Receptor expression in prostate cancer patients

How effective was ANGLE's AR expression assay in clinical testing?

The assay showed high sensitivity, with 50% of tested mCRPC patients being CTC-positive, and all CTC-positive patients had AR-positive CTCs, enabling AR expression assessment

What is the market potential for ANPCY's AR inhibitor technology?

The AR inhibitor market is projected to reach US $9.8 billion by 2032, with at least 130 ongoing clinical studies

How does ANGLE's new AR assay demonstrate drug response?

The assay showed AR expression reduction from over 80% AR-positive cells in untreated samples to under 20% at the highest drug level, demonstrating clear treatment response monitoring capability

What are the commercial applications of ANGLE's new AR expression assay?

The assay is now available as part of ANGLE's menu to support pharmaceutical companies with longitudinal biomarker assessment in AR-targeted clinical trials